The condition

Multiple sclerosis relapses: why an ACTH gel is still on the label

Repository corticotropin, a long-acting ACTH gel, is labelled for acute exacerbations of multiple sclerosis in adults. High-dose corticosteroids are the usual relapse treatment. A small placebo-controlled trial in people who had not responded to steroids found more disability-scale responders on the gel. ACTH is a melanocortin; how much of the effect is cortisol, and how much is direct, is still debated.

By melanocortin.com editorialLast updated 2026

A relapse is a flare of inflammation in the central nervous system. The oldest melanocortin drug is still licensed to quiet one — mostly, everyone agrees, by making the adrenal release cortisol.

Multiple sclerosis is an immune disease of the central nervous system. A relapse is a new or worsening neurological deficit that lasts, caused by a fresh focus of inflammation. It is not, by itself, a melanocortin disease. It is on this site because repository corticotropin — ACTH in a slow-release gel — is FDA-labelled for the treatment of acute exacerbations of MS in adults.[1] The same preparation’s other famous inflammatory use is symptomatic sarcoidosis.

An indirect steroid, and maybe something else

ACTH is cut from POMC. Injected, it binds MC2R on the adrenal cortex and the cortex releases cortisol. For most of the drug’s history that was the whole explanation: Acthar is a way of making the patient produce their own steroid.[3] High-dose corticosteroids are still the standard drug for an MS relapse that needs treating. The gel sits beside that, not in front of it, and its price has been a long-running argument of its own.[3]

The melanocortin-specific claim is the extra one. Receptors of this family are also expressed on immune cells, and a steroid-independent anti-inflammatory effect has been invoked to explain why an ACTH preparation might help when a steroid already has not. The therapeutics page keeps the score on that debate. It is plausible pharmacology. It is not, on current evidence, a proven second mechanism you can point to in a patient.

The trial in steroid non-responders

The study that matches the “when steroids fail” use (NCT03126760) enrolled adults with relapsing-remitting MS whose relapse had not responded adequately to high-dose corticosteroids. Thirty-five people were randomised: 18 to 80 units of the gel daily for 14 days, 17 to placebo. At day 42, 61% of the gel group and 12% of the placebo group met the disability-scale (EDSS) responder definition. A clinician global impression leaned the same way. The MS Impact Scale did not show a meaningful difference, and there were no serious adverse events in the report.[2]

Read the size. Thirty-five people, one positive scale, one scale that did not move. That is evidence the gel can do something in a relapse that shrugged off steroids. It is not evidence that it should replace corticosteroids, and it says nothing about preventing the next relapse. Disease-modifying MS drugs are a different category entirely, and none of them is a melanocortin.

The honest bottom line

Acute MS relapse is a labelled use of an old ACTH drug. The melanocortin content is the peptide and the receptor that turns it into cortisol, plus an unresolved claim about immune-cell receptors. For the hormone, see ACTH; for the receptor, MC2R; for every other condition on this map, the conditions page.

Education, not a protocol

This page explains a labelled use of repository corticotropin. It is not medical advice and gives no dosing or treatment instructions. An MS relapse needs clinical care. See the editorial standards.

Common questions

Why is multiple sclerosis on a melanocortin site?

Because repository corticotropin, a long-acting ACTH gel, is FDA-labelled for acute exacerbations of multiple sclerosis in adults. ACTH is a melanocortin peptide cut from POMC. High-dose corticosteroids are the usual treatment for a relapse; the gel is an alternative, including when steroids have not worked.

Does ACTH treat MS itself?

No. The label is for acute relapses, not for preventing them and not as a disease-modifying therapy. Modern MS care uses other drugs for that job. This page is about the relapse indication only.

What did the modern trial show?

A small placebo-controlled study enrolled 35 adults whose relapse had not responded adequately to high-dose corticosteroids. More people on the gel than on placebo improved on a disability scale by day 42 (about 61% versus about 12%). A quality-of-life scale did not separate. Thirty-five people is a signal, not a definitive trial.

Is the benefit just cortisol?

Partly, and maybe not only. ACTH drives the adrenal to release cortisol through MC2R, so the gel is at least an indirect steroid. Melanocortin receptors also sit on immune cells, and a steroid-independent effect has been proposed. How much of the clinical effect that accounts for is unresolved.

References

  1. 1.US FDA / DailyMed. ACTHAR (repository corticotropin injection) prescribing information — labelled for acute exacerbations of multiple sclerosis in adults. Label. 2024. link ↗
  2. 2.Wynn D, Goldstick L, Bauer W, et al. Results from a multicenter, randomized, double-blind, placebo-controlled study of repository corticotropin injection for multiple sclerosis relapse that did not adequately respond to corticosteroids. CNS Neurosci Ther. 28(3):364–371. NCT03126760; 35 randomised. Sponsor-supported. 2022. link ↗
  3. 3.Gettig J, Cummings JP, Matuszewski K. H.P. Acthar Gel and cosyntropin review: clinical and financial implications. P T. 34(5):250–257. 2009. link ↗